ArticleMolecular neurobiology2025
Serum Metabolites as Mediator Between Autoimmune Hyperthyroidism and Epilepsy: A Mendelian Randomization Analysis.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Epilepsy, a complex neurological condition, might intertwine with various immune system anomalies, including autoimmune hyperthyroidism. An overactive thyroid gland due to immune system misdirection could subtly influence epilepsy via mechanisms not fully understood. Our investigation leverages Mendelian randomization (MR) to dissect this association, aiming to illuminate the role of serum metabolites as a possible bridge connecting these conditions. A comprehensive MR analysis was conducted in three phases, using genetic variants from GWAS datasets. The first phase assessed the causal effect of autoimmune hyperthyroidism on epilepsy. The second phase examined the impact of 1400 serum metabolites on epilepsy. The final phase explored the mediation of these metabolites in the autoimmune hyperthyroidism-epilepsy pathway. The analysis employed inverse variance weighted (IVW) methods, along with sensitivity analyses including MR-Egger and weighted median approaches, to ensure robustness. Our Mendelian randomization analysis identifies a significant causal relationship from autoimmune hyperthyroidism to epilepsy. We observed that genetic predisposition towards autoimmune hyperthyroidism is associated with reduced risk of developing epilepsy (P = 0.037). Sensitivity analyses, such as culling analysis and funnel plot inspections, confirm the consistency and robustness of this finding. Further analysis revealed cAMP as a mediator in this causal pathway (P = 0.016), underscoring its role in the link between autoimmune hyperthyroidism and epilepsy. Conversely, no causal effect of epilepsy on the development of autoimmune hyperthyroidism was found, highlighting a unidirectional relationship. This study proposes that autoimmune hyperthyroidism may act as a protective factor against epilepsy, with this effect potentially mediated by serum metabolites, particularly cAMP. These findings provide novel insights into the interplay between autoimmune conditions, metabolic alterations, and neurological disorders, highlighting cAMP as a promising therapeutic target of epilepsy.
Indexed as
Identifiers
40169517What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.